Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents
Authors: Rahman Shah
Journal: Annals of Internal Medicine (2016)

Letters6 December 2016Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic StentsRahman Shah, MDRahman Shah, MDFrom Veterans Affairs Medical Center and University of Tennessee, Memphis, Tennessee.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0420 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Zhang and colleagues (1) conclude that everolimus-eluting bioresorbable vascular scaffolds (BVSs) pose a greater risk for stent thrombosis and myocardial infarction than everolimus-eluting metallic stents (EESs). This conclusion is somewhat misleading, because their best evidence was obtained from randomized, controlled trials (RCTs), not observational studies (2). In their analysis, summary results were not significant for RCTs. Their overall summary result (combined for observational studies and RCTs) seems to have been driven by data from observational studies. ...References1. Zhang XL, Zhu L, Wei ZH, Zhu QQ, Qiao JZ, Dai Q, et al. Comparative efficacy and safety of everolimus-eluting bioresorbable scaffold versus everolimus-eluting metallic stents: a systematic review and meta-analysis. Ann Intern Med. 2016;164:752-63. [PMID: 27042809]. doi:10.7326/M16-0006 LinkGoogle Scholar2. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? [Editorial]. N Engl J Med. 2000;342:1907-9. [PMID: 10861329] CrossrefMedlineGoogle Scholar3. Colombo A, Ruparelia N. Who is thrombogenic: the scaffold or the doctor? Back to the future! [Editorial]. JACC Cardiovasc Interv. 2016;9:25-7. [PMID: 26762907] doi:10.1016/j.jcin.2015.09.021 CrossrefMedlineGoogle Scholar4. Puricel S, Cuculi F, Weissner M, Schmermund A, Jamshidi P, Nyffenegger T, et al. Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. J Am Coll Cardiol. 2016;67:921-31. [PMID: 26916481] doi:10.1016/j.jacc.2015.12.019 CrossrefMedlineGoogle Scholar5. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al; ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373:1905-15. [PMID: 26457558] doi:10.1056/NEJMoa1509038 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Veterans Affairs Medical Center and University of Tennessee, Memphis, Tennessee.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L16-0420. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoComparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents Xin-Lin Zhang , Li Zhu , Zhong-Hai Wei , Qing-Qing Zhu , Jian-Zhong Qiao , Qing Dai , Wei Huang , Xiao-Hong Li , Jun Xie , Li-Na Kang , Lian Wang , and Biao Xu Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents Xin-Lin Zhang and Biao Xu Metrics 6 December 2016Volume 165, Issue 11Page: 828-829KeywordsConflicts of interestDisclosureMyocardial infarctionObservational studiesOptical coherence tomographyPlatelet activationRisk managementStent implantationThrombosisUltrasound imaging ePublished: 6 December 2016 Issue Published: 6 December 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...